Teva Pharmaceutical Industries Ltd. on Tuesday reported third-quarter results that exceeded analyst profit estimates and raised its 2026 revenue outlook, as sales of three branded medicines offset weaker generics, Reuters reported and the company said in its earnings release^1,2.

The Israeli drugmaker posted non-GAAP diluted earnings of 86 cents a share and revenue of $4.4 billion for the quarter ended Sept. 30, according to Teva². Reuters, citing LSEG data, said analysts had expected 72 cents a share on $4.22 billion of sales¹.

GAAP net income attributable to Teva was $233 million, or 20 cents a share, down from $433 million, or 37 cents, a year earlier². Revenue fell 2% from a year earlier in both dollars and local currency, Teva said².

Teva raised its 2026 revenue forecast to $16.7 billion to $17.0 billion^1,2. Reuters said the lift reflected higher projections for branded drugs Austedo, Ajovy and Uzedy¹. The company also guided to non-GAAP diluted EPS of $1.92 to $2.11 for 2026^1,2.

Austedo, Ajovy and Uzedy together generated about $1.1 billion in the quarter, up 33% year over year in local currency, Teva said². Austedo sales were $751 million, Ajovy $269 million and Uzedy $85 million, and Teva raised full-year outlooks for each².

Generics revenue declined, Teva said, mainly because of competition for lenalidomide capsules, a generic of Revlimid, in the United States². Reuters likewise attributed the profit beat to branded sales offsetting generic declines¹. Teva said it now expects more than $800 million in biosimilars revenue in 2026, a year earlier than its prior 2027 target².

Chief Executive Richard Francis said the quarter showed the company’s “Pivot to Growth” strategy and that the three brands’ growth supported raising 2026 brand outlooks².

Teva also said the FDA approved Weltruza, a once-monthly injectable for schizophrenia in adults, in October 2026, and that it stopped a Phase 2 study of emrusolmin in multiple system atrophy after an interim futility analysis². What the stock did after the report was not detailed in the sources used here^1,2.

Sources

1. ReutersTeva profit beats forecasts, raises 2026 revenue estimatesNov 3, 12:45 PM
2. Teva Pharmaceutical IndustriesTeva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO, AJOVY and UZEDYNov 3, 7:00 AM

Read the original at Reuters ↗